Aptinyx (NASDAQ:APTX) Price Target Cut to $4.00 by SVB Leerink Analysts
Aptyx (NASDAQ:APTX – Get a rating) had its price target reduced by SVB Leerink from $10.00 to $4.00 in a research note released to investors on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. SVB Leerink’s price target would indicate a potential upside of 277.36% from the current share price.
APTX has been the subject of several other research reports. BMO Capital Markets cut its price target on Aptinyx shares from $12.00 to $6.00 in a Friday, April 8 research report. Zacks Investment Research upgraded Aptinyx shares from a “hold” to a “buy” rating and set a price target of $1.25 on the stock in a research report on Wednesday. HC Wainwright cut its price target on Aptinyx shares from $8.00 to $2.00 and set a “buy” rating on the stock in a Thursday, April 14 research report. Cantor Fitzgerald cut his price target on Aptinyx shares from $11.00 to $5.00 and set an “overweight” rating on the stock in a Friday, April 8 research report. Finally, William Blair downgraded Aptinyx shares from an “outperforming” rating to a “market performing” rating in a Thursday, April 7 research report. One investment analyst gave the stock a hold rating and five gave the company’s stock a buy rating. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $3.88.
APTX traded down $0.03 during Thursday trading hours, hitting $1.06. The company’s stock had a trading volume of 343,546 shares, compared to an average volume of 366,159. The company’s 50-day moving average price is $2.61 and its 200-day moving average price is $2.59. Aptinyx has a 12-month low of $0.90 and a 12-month high of $4.73. The stock has a market capitalization of $71.78 million, a price-earnings ratio of -0.95 and a beta of 1.09. The company has a current ratio of 20.18, a quick ratio of 20.18 and a debt ratio of 0.15.
Aptyx (NASDAQ:APTX – Get a rating) last announced its quarterly results on Wednesday, March 23. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.06. In the same quarter a year earlier, the company posted ($0.20) earnings per share. On average, analysts expect Aptinyx to post -1.15 earnings per share for the current year.
Institutional investors and hedge funds have recently changed their holdings in the company. BlackRock Inc. increased its stake in Aptinyx shares by 1.5% during the fourth quarter. BlackRock Inc. now owns 1,374,768 shares of the company valued at $3,669,000 after purchasing an additional 20,928 shares during the period. Millennium Management LLC increased its equity stake in Aptinyx by 19.7% during the fourth quarter. Millennium Management LLC now owns 1,246,945 shares of the company valued at $3,329,000 after purchasing an additional 205,553 shares during the period. Susquehanna International Group LLP increased its stake in Aptinyx shares by 56.8% during the fourth quarter. Susquehanna International Group LLP now owns 243,275 shares of the company valued at $650,000 after purchasing an additional 88,141 shares during the period. Dimensional Fund Advisors LP increased its stake in Aptinyx by 5.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 123,937 shares of the company worth $331,000 after acquiring an additional 6,133 shares during the period. Finally, Charles Schwab Investment Management Inc. acquired a new stake in Aptinyx in the fourth quarter worth approximately $54,000. 50.34% of the shares are held by hedge funds and other institutional investors.
About Aptinyx (Get a rating)
Aptinyx Inc, a clinical-stage biopharmaceutical company, is focused on the discovery, development and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in phase II/b clinical trials for the treatment of fibromyalgia.
Get news and reviews for Aptinyx Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Aptinyx and related companies with MarketBeat.com’s free daily email newsletter.